117 related articles for article (PubMed ID: 25394094)
1. Potential implications of CYP3A4, CYP3A5 and MDR-1 genetic variants on the efficacy of Lopinavir/Ritonavir (LPV/r) monotherapy in HIV-1 patients.
Berno G; Zaccarelli M; Gori C; Tempestilli M; Pucci L; Antinori A; Perno CF; Pucillo LP; D'Arrigo R
J Int AIDS Soc; 2014; 17(4 Suppl 3):19589. PubMed ID: 25394094
[TBL] [Abstract][Full Text] [Related]
2. Influence of MDR1 C1236T polymorphism on lopinavir plasma concentration and virological response in HIV-1-infected children.
Bellusci CP; Rocco C; Aulicino P; Mecikovsky D; Curras V; Hegoburu S; Bramuglia GF; Bologna R; Sen L; Mangano A
Gene; 2013 Jun; 522(1):96-101. PubMed ID: 23528223
[TBL] [Abstract][Full Text] [Related]
3. Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs.
Berno G; Zaccarelli M; Gori C; Tempestilli M; Antinori A; Perno CF; Pucillo LP; D'Arrigo R
BMC Med Genet; 2014 Jul; 15():76. PubMed ID: 24986243
[TBL] [Abstract][Full Text] [Related]
4. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.
Rakhmanina NY; Neely MN; Van Schaik RH; Gordish-Dressman HA; Williams KD; Soldin SJ; van den Anker JN
Ther Drug Monit; 2011 Aug; 33(4):417-24. PubMed ID: 21743379
[TBL] [Abstract][Full Text] [Related]
5. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
Lubomirov R; di Iulio J; Fayet A; Colombo S; Martinez R; Marzolini C; Furrer H; Vernazza P; Calmy A; Cavassini M; Ledergerber B; Rentsch K; Descombes P; Buclin T; Decosterd LA; Csajka C; Telenti A;
Pharmacogenet Genomics; 2010 Apr; 20(4):217-30. PubMed ID: 20139798
[TBL] [Abstract][Full Text] [Related]
6. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
Bunupuradah T; Chetchotisakd P; Ananworanich J; Munsakul W; Jirajariyavej S; Kantipong P; Prasithsirikul W; Sungkanuparph S; Bowonwatanuwong C; Klinbuayaem V; Kerr SJ; Sophonphan J; Bhakeecheep S; Hirschel B; Ruxrungtham K;
Antivir Ther; 2012; 17(7):1351-61. PubMed ID: 23075703
[TBL] [Abstract][Full Text] [Related]
7. Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients.
Solas C; Simon N; Drogoul MP; Quaranta S; Frixon-Marin V; Bourgarel-Rey V; Brunet C; Gastaut JA; Durand A; Lacarelle B; Poizot-Martin I
Br J Clin Pharmacol; 2007 Sep; 64(3):353-62. PubMed ID: 17517050
[TBL] [Abstract][Full Text] [Related]
8. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia.
Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Biswas NR; Gupta YK
Pharmacol Res; 2017 Jun; 120():138-145. PubMed ID: 28330783
[TBL] [Abstract][Full Text] [Related]
9. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
Loh PT; Lou HX; Zhao Y; Chin YM; Vathsala A
Transplant Proc; 2008 Jun; 40(5):1690-5. PubMed ID: 18589174
[TBL] [Abstract][Full Text] [Related]
10. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation.
Anglicheau D; Thervet E; Etienne I; Hurault De Ligny B; Le Meur Y; Touchard G; Büchler M; Laurent-Puig P; Tregouet D; Beaune P; Daly A; Legendre C; Marquet P
Clin Pharmacol Ther; 2004 May; 75(5):422-33. PubMed ID: 15116055
[TBL] [Abstract][Full Text] [Related]
11. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
[TBL] [Abstract][Full Text] [Related]
12. Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients.
Elens L; Yombi JC; Lison D; Wallemacq P; Vandercam B; Haufroid V
Pharmacogenomics; 2009 Oct; 10(10):1589-97. PubMed ID: 19842932
[TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV.
Ma Q; Brazeau D; Zingman BS; Reichman RC; Fischl MA; Gripshover BM; Venuto CS; Slish JC; DiFrancesco R; Forrest A; Morse GD
Pharmacogenomics; 2007 Mar; 8(3):227-35. PubMed ID: 17324111
[TBL] [Abstract][Full Text] [Related]
14. [Lopinavir/ritonavir in HIV-infected patient with long-term virological failure: immunovirological response and tolerance in 121 patients of the ANRS CO8 Aproco-Copilote cohort].
Brunet-François C; Taieb A; Masquelier B; Le Moing V; Lewden C; Dellamonica P; Cuzin L; Allavena C; Spire B; Chêne G; Raffi F;
Med Mal Infect; 2007 Mar; 37(3):172-7. PubMed ID: 17239554
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir.
Bunupuradah T; Bowonwattanuwong C; Jirajariyavej S; Munsakul W; Klinbuayaem V; Sophonphan J; Mahanontharit A; Hirschel B; Ruxrungtham K; Ananworanich J;
Antivir Ther; 2014; 19(6):579-86. PubMed ID: 24464590
[TBL] [Abstract][Full Text] [Related]
16. MDR1 C3435T polymorphism in patients with breast cancer.
Turgut S; Yaren A; Kursunluoglu R; Turgut G
Arch Med Res; 2007 Jul; 38(5):539-44. PubMed ID: 17560460
[TBL] [Abstract][Full Text] [Related]
17. Differences in genetic variants in lopinavir disposition among HIV-infected Bantu Africans.
Mpeta B; Kampira E; Castel S; Mpye KL; Soko ND; Wiesner L; Smith P; Skelton M; Lacerda M; Dandara C
Pharmacogenomics; 2016 May; 17(7):679-90. PubMed ID: 27142945
[TBL] [Abstract][Full Text] [Related]
18. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
Hill A; Marcelin AG; Calvez V
HIV Med; 2009 Nov; 10(10):620-6. PubMed ID: 19601995
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
[TBL] [Abstract][Full Text] [Related]
20. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
